IN8bio, Inc. (NASDAQ:INAB) Short Interest Up 13.6% in August

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 278,200 shares, a growth of 13.6% from the July 31st total of 244,900 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 387,400 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $12.50 price target on shares of IN8bio in a report on Friday, June 14th.

IN8bio Stock Up 1.4 %

Shares of INAB stock traded up $0.01 during trading hours on Friday, hitting $0.53. 59,401 shares of the company’s stock traded hands, compared to its average volume of 315,243. The stock has a market cap of $23.23 million, a price-to-earnings ratio of -0.58 and a beta of 0.06. The stock’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.99. IN8bio has a 12-month low of $0.50 and a 12-month high of $2.48. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.02.

IN8bio (NASDAQ:INAB) last posted its earnings results on Thursday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, analysts expect that IN8bio will post -0.6 EPS for the current year.

Hedge Funds Weigh In On IN8bio

A hedge fund recently bought a new stake in IN8bio stock. AIGH Capital Management LLC bought a new position in shares of IN8bio, Inc. (NASDAQ:INAB) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,098,361 shares of the company’s stock, valued at approximately $5,216,000. IN8bio comprises about 2.1% of AIGH Capital Management LLC’s investment portfolio, making the stock its 20th largest holding. AIGH Capital Management LLC owned approximately 12.81% of IN8bio at the end of the most recent reporting period. 92.05% of the stock is currently owned by hedge funds and other institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.